



**World Health  
Organization**

INN Working Document 26.638  
06/02/2026

**Addendum\* to  
"The use of stems in the selection of International  
Nonproprietary Names (INN) for pharmaceutical  
substances, 2024"**

ISBN 9-789240-099388

***Programme on International Nonproprietary Names (INN)***

***Product Standards, Specifications and Nomenclature Unit (PSN)  
Medicines and Health Products Policies and Standards Department (HPS)  
Health Systems, Access and Data Division (HSD)***

***World Health Organization, Geneva***

© World Health Organization 2026 - All rights reserved. The contents of this document may not be reviewed, abstracted, quoted, referenced, reproduced, transmitted, distributed, translated or adapted, in part or as a whole, in any form or by any means, without explicit prior authorization of the WHO INN Programme.  
This document contains the collective views of the INN Expert Group and does not necessarily represent the decisions or the stated policy of the World Health Organization.

## Addendum\* to "The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances" - ISBN 9-789240-099388

\* This addendum is a cumulative list of all new stems selected by the INN Expert Group since the publication of "The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances" 2024.

|                       |                                                                                                                                                                                                                                                                                                                 |
|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>-alkib</b>         | <p><b>ALK (anaplastic lymphoma kinase) inhibitors</b><br/> dirozalkib (132), envonalkib (126), ficonalkib (128), neladalkib (130), iruplinalkib (126), zotizalkib (128)</p> <p>under (c) category: alectinib (108), brigatinib (113), ceritinib (109), crizotinib (103), ensartinib (115), nasartinib (115)</p> |
| <b>-ampator</b>       | <p><b><math>\alpha</math>-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor modulators</b><br/> farampator (92), mibampator (103), osavampator (129), pesampator (126), tulrampator (116)</p>                                                                                                  |
| <b>-cirnon</b>        | <p><b>CC chemokine receptor (CCR) antagonists</b><br/> ilacirnon (123), lazucirnon (123), tivumecirnon (128), vercirnon (107), zelnecirnon (130)</p>                                                                                                                                                            |
| <b>defer-/-defer-</b> | <p><b>iron chelating agents deferitrin (or desferrithiocin) derivatives,</b><br/> cideferron (39), deferiprone (67), deferitazole (108), deferitrin (92), petadeferitrin (132)<br/> <b>others:</b> deferoxamine (14)(!), deferasirox (86)</p>                                                                   |
| <i>gli</i>            | <i>antihyperglycaemics</i>                                                                                                                                                                                                                                                                                      |
| <b>-glipron</b>       | <p><b>glucagon-like peptide 1 receptor (GLP1R) agonists</b><br/> aleniglipron (131), conveglipron (134), danuglipron (124), elecoglipron (132), lotiglipron (129), naperiglipron (134), orforglipron (128), safiglipron (134), tifeglipron (134)</p>                                                            |
| <b>-menin</b>         | <p><b>menin interaction inhibitors</b><br/> balomenib (132), bleximenib (129), emilumenib (129), enzomenib (130), icovamenib (130), revumenib (126), zefamenib (133)(!), ziftomenib (127)</p>                                                                                                                   |
| <b>-meran</b>         | <i>mRNA</i>                                                                                                                                                                                                                                                                                                     |
| <b>-vameran</b>       | <p><b>prophylactic vaccines</b><br/> breto vameran (131), cemivameran (132), lonpovameran (131), quozovameran (133), rubravameran (132), tagovameran (132)<br/> under b) category: acavameran (124)</p>                                                                                                         |
| <b>-nosine</b>        | <p><b><u>purine</u> nucleoside analogues, antivirals or antineoplastics</b><br/> adenosine phosphate (14), ateganosine (130), didanosine (64), fosdesdenosine sipalabenamide (130), inosine (42), lodenosine (78)<br/> (b) category: alanosine (48)</p>                                                         |

|                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>-orexton</b>  | <b>orexin receptor agonists</b><br>alixorexton (132), balumorexton (134), clemimorexton (133),<br>danavorexton (123), firazorexton (123), ledasorexton (133),<br>oveporexton (131), suntinorexton (123)                                                                                                                                                                                                                                                                                                                                                                   |
| <b>-patide</b>   | see <i>-tide</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>-protafib</b> | <b>human protein tyrosine phosphatase (HPTP) inhibitors</b><br>batoprotafib (127), ertiprotafib (87), migoprotafib (129), osunprotafib<br>(129), razuprotafib (116), sitneprotafib (133), tegeprotafib (129),<br>vociprotafib (127)                                                                                                                                                                                                                                                                                                                                       |
| <b>-rogant</b>   | <b>retinoic acid receptor-related orphan receptor gamma (ROR<math>\gamma</math>)<br/>antagonists and inverse agonists</b><br>bevurogant (125), cedirogant (123), izumerogant (128), retezorogant<br>(126), vimirogant (120)                                                                                                                                                                                                                                                                                                                                               |
| <b>-stat</b>     | enzyme inhibitors                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>-drostat</b>  | <b>inhibitors of the synthesis of aldosterone and cortisol</b><br>osilodrostat (110), baxdrostat (125), dexfadrostat (126),<br>lorundrostat (127), vicadrostat (130)                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>-terkib</b>   | <b>extracellular signal-regulated kinase (ERK) inhibitors</b><br>beroterkib (131), edaxeterkib (126), rineterkib (123), sonvuterkib<br>(133), temuterkib (125), tizaterkib (125)<br>under (c) category: ravoxertinib (115), ulixertinib (113)                                                                                                                                                                                                                                                                                                                             |
| <b>-tide</b>     | peptides                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>-patide</b>   | <b>gastric inhibitory polypeptide (glucose-dependent insulinitropic<br/>polypeptide, GIP) receptor agonists with or without GLP-1<br/>receptor agonist activity</b><br>acmopatide (133), astepatide (132), brenipatide (134), enicepatide<br>(133), ganipatide (129), macupatide (132), olatorepatide (130),<br>poterepatide (134), relsipatide (133), ribupatide (133), tirzepatide<br>(120)<br><b>under c) category: cenupatide (119)</b>                                                                                                                               |
| <b>-lintide</b>  | <b>amylin receptor agonists including dual amylin / calcitonin<br/>receptor agonists</b><br>amlintide (76), batelintide (134), cagrilintide (123), colulintide (132),<br>davalintide (101), eloralintide (131), lenbelintide (133), petrelintide<br>(129), pramlintide (74)                                                                                                                                                                                                                                                                                               |
| <b>-votide</b>   | <b>PSMA (prostate-specific membrane antigen, glutamate<br/>carboxypeptidase 2)-binding peptides</b><br>actinium ( <sup>225</sup> Ac) vipivotide tetraxetan (133), actinium ( <sup>225</sup> Ac)<br>felivotide mopaxetan (133), actinium ( <sup>225</sup> Ac) zadavotide guraxetan<br>(132), copper ( <sup>64</sup> Cu) zadavotide guraxetan (133), lutetium ( <sup>177</sup> Lu)<br>pocuvotide satetaxetan (133), lutetium ( <sup>177</sup> Lu) tezuvootide tetraxetan<br>(131), lutetium ( <sup>177</sup> Lu) vipivotide tetraxetan (127), lutetium ( <sup>177</sup> Lu) |

zadavotide guraxetan (130), sonzivotide filricianine (132), vipivotide tetraxetan (130), sonzivotide filricianine (132), vipivotide tetraxetan (130)

*-tinib*

tyrosine kinase inhibitors

*-gratinib*

**fibroblast growth factor receptors (FGFR) inhibitors**

dabogratinib (132), fanregratinib (131), gunagratinib (125), infigratinib (112), ratangratinib (132), tasurgratinib (124), vepugratinib (134), zoligratinib (122)

**under (c) category:** futabatinib (119), pemigatinib (118), rogaratinib (115)

*-turev*

**under the advanced therapy scheme for: oncolytic viruses**

canerpaturev (117), gebasaxturev (126), lerapolturev (125), linoserpaturev (131), suratadenoturev (123), tasadenoturev (117), tesserpaturev (119)

**under (c) category:** enadenotucirev (111)

*-vameran*

see *-meran*

*-vatein*

**protein vaccine substances**

*-covatein*

**coronavirus**

carocovatein (128), enlicovatein (128), girocovatein (133), laricovatein (128), meracovatein (134), riticovatein (128), tibrecovatein (128)

inter-related INN:

*-alsecovatein* (128), *mivalsecovatein* (131), *upalsecovatein* (129)

*-selvacovatein* (128), *damlecovatein* (131)

*-sorimcovatein* (128), *pesorimcovatein* (130), *tisorimcovatein* (130)

*-vir*

antivirals

*-trelvir*

**antiviral 3CL protease inhibitors**

abimtrelovir (126), atilotrelvir (129), bofutrelvir (127), deunirmatrelovir (129), ensitrelvir (126), ibuzatrelovir (129), imocitrelvir (130), iscartrelvir (130), limnetrelvir (130), lufotrelvir (125), nirmatrelovir (126), olgotrelvir (129), pomotrelvir (127), ratutrelvir (132), secutrelvir (132), zevotrelvir (129)

\*\*\*\*\*

\*\*\*\*\*

**Changes were also made in the following stems' definitions:**

**-cianine**

from *indocyanine fluorescence dye group*  
to *cyanine dyes and their derivatives, diagnostic imaging agents*

**-fylline**

from *N-methylated xanthine derivatives*  
to *N-alkylated xanthine derivatives*

**-ilide**

from *class III antiarrhythmics, sematilide derivatives*  
to *class III antiarrhythmics, ~~sematilide derivatives~~*

**-kalim**

from *potassium channel activators, antihypertensives.*  
to *potassium channel activators, ~~antihypertensives.~~*

**-kinra**

from *interleukin receptor antagonists and interleukin antagonists*  
to *interleukin receptor antagonists and interleukin inhibitors*

**-(o)nidine**

from *antihypertensives, clonidine derivatives*  
to  *$\alpha_2$  adrenoreceptor agonists*

under *-relin*

**-morelin**

from *growth hormone release-stimulating peptides*  
to *growth hormone release-stimulating substances*

under *-rsen*

**-dirsten**

from *targeting muscular dystrophies*  
to *splice-switching oligonucleotides, muscular dystrophies*

under *-tant*

**-netant**

from *neurokinin NK3 receptor antagonists*  
to *neurokinin NK3 and dual NK3-NK1 receptor antagonists*

**-tirom(e)** (future use of final (e) is discouraged to avoid conflict with -terone stem)

from *antihyperlipidemic, thyromimetic derivatives*  
to *~~antihyperlipidemic~~, thyromimetic derivatives*

**-zomib**

from *proteasome inhibitors*  
to *human proteasome inhibitors*

Changes were also made in the stem's infix:

**-gromab (under -mab)**

from *-gros*mab

for the designation of INN for monoclonal antibodies targeting skeletal muscle mass related growth factors and receptors

**-ki- (under -mab)**

from the designation of INN for monoclonal antibodies targeting interleukins,  
to cytokine and cytokine receptors

**Please note that a new naming scheme for monoclonal antibodies** was adopted at the 73<sup>rd</sup> INN Consultation. The document can be retrieved here after and from our webpages at:  
[https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-\(inn\)/new\\_mab\\_-nomenclature-\\_2021.pdf?sfvrsn=207e78cb\\_12&download=true](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/new_mab_-nomenclature-_2021.pdf?sfvrsn=207e78cb_12&download=true)